利妥昔单抗联合化疗治疗弥漫型大B细胞淋巴瘤患者的临床疗效

Clinical Efficacy of Rituximab Combined With Chemotherapy in the Treatment of Patients With Diffuse Large B Cell Lymphoma

目的研究分析利妥昔单抗联合化疗对弥漫型大B细胞淋巴瘤患者的应用效果。方法选择我院2014年8月-2015年8月收治的28例弥漫型大B细胞淋巴瘤患者作为研究对象,随机分为观察组和对照组,观察组患者接受利妥昔单抗联合化疗的治疗,对照组患者仅接受利妥昔单抗治疗,对比临床疗效。结果观察组患者发热率高于对照组患者,治疗有效率为78.57%,高于对照组患者的42.86%,以上组间比较差异具有统计学意义（P〈0.05）;两组患者胃肠道反应、白细胞减少发生率之间的比较差异无统计学意义（P〉0.05）。结论利妥昔单抗联合化疗对弥漫型大B细胞淋巴瘤具有良好的治疗效果,可有效提高患者治疗有效率,不会使患者出现严重的不良反应。

Objective To study the effect of rituximab combined with chemotherapy on patients with diffuse large B cell lymphoma. Methods In our hospital from August 2014 to August 2015, 28 cases of diffuse large B cell lymphoma patients as the research object, randomly divided into the observation group and the control group, patients in the observation group received the treatment of rituximab combined with chemotherapy, patients in the control group only received rituximab therapy. The clinical efficacy was compared. Results In the observation group patients with fever rate higher than that of the control group, the effective rate of treatment was 78.57%, higher than that of the control group were 42.86%, the difference between the above groups has statistical significance（P〈0.05）, two groups of patients with gastrointestinal reactions, leukocyte reduction occurred rate between the difference was not statistically significant（P〉0.05）. Conclusion Rituximab combined with chemotherapy for diffuse large B cell lymphoma has a good therapeutic effect, can effectively improve the patient＇s treatment efficiency, and will not cause serious adverse reactions in patients.